Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis

Study Title
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva Identifier
ALS-GA-201
ClinicalTrials.gov Identifier
NCT00326625
Study Status
Completed
Trial Condition(s)
Amyotrophic Lateral Sclerosis
Interventions
Drug: 40 mg glatiramer acetate | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Print

Participation criteria and map of study locations
brain-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 70 Years
Trial Duration
July 31, 2006 - July 31, 2008
Phase
Phase 2

Study Type

Interventional